Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, sales was INR 2,761.56 million compared to INR 3,128.17 million a year ago. Revenue was INR 2,812.89 million compared to INR 3,302.02 million a year ago. Net income was INR 56.55 million compared to INR 129.66 million a year ago. Basic earnings per share from continuing operations was INR 3.57 compared to INR 8.19 a year ago. Diluted earnings per share from continuing operations was INR 3.57 compared to INR 8.19 a year ago.